设为首页         

资讯内容 Content

[ESC2009]ACCOMPLISH的影响及单片复方制剂(SPC)在临床中的应用--Dahlof教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/3 19:00:00    加入收藏
 关键字:KYOTO HEART Dahlof 倍博特 阿利吉仑 


International Circulation:  Finally, I know that there are side effects with amlodipine mono therapies so how significant is it? If there is a real improvement when we have the combination together with amlodipine?

国际循环:最后,我知道氨氯地平单一疗法有一定的不良反应,这到底有多大意义?与氨氯地平联合是否真的有所改善?

Dahlof:  I mean the improvement is not only with the figures, the improvement is also that you have less side effects and I think that it one advantage that many forget.  Amlodipine has this advantage of ankle edema when you give it together of a blocker of renin angiotensin system you can half or even two thirds the number of patients who have problems with ankle edema.  So I think it is a real advantage that you have more efficacious medication that is based on a very good mechanistic complimentary action of the two drugs in addition to being better tolerated than mono therapy can be especially mono therapy of calcium channel blocker.  


 Dahlof:我说的改善不单指临床数据,同时可以减少不良反应,这也是常被忽略的。氨氯地平与肾素血管紧张素拮抗剂联用,可缓和1/2至2/3患者的踝部水肿。这是基于两种药物机制的有益互补,获得比单一疗法尤其是钙通道阻断剂单一疗法更好的耐受性。



上一页  [1]  [2]  [3]  [4]  

 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved